CPIC

CPIC has published therapeutic guidelines for rasburicase based on G6PD genotype. Rasburicase is a drug that lowers uric acid levels and is used to treat or prevent hyperuricemia in cancer patients undergoing chemotherapy, and in newborns to prevent kidney damage. It is contraindicated for use in patients with G6PD deficiency

Clinpharmpod is the clinical pharmacology podcast from the journal Clinical Pharmacology and Therapeutics produced in association with Nature Publishing Group. In the March 25th episode from Clinpharmpod, host Geoff Marsh interviews Dr. Mary Relling on the history and future plans for the Clinical Pharmacogenetics Implementation Consortium (CPIC). A joint effort

The American Society of Health-System Pharmacists (ASHP) will be hosting a live webinar on Tuesday, April 15th from 2:00 - 3:00 pm EST discussing the Clinical Pharmacogenetics Implementation Consortium (CPIC). The webinar will be presented by Kelly E. Caudle, CPIC coordinator at St. Jude Children's Research

Cystic fibrosis (CF) therapy has traditionally been based on the treatment of symptoms and infections, rather than targeting the underlying defect caused by variants in the CFTRgene. Ivacaftor is the first FDA-approved drug to specifically target a particular defect of the CFTR protein. It is indicated for use in patients

CPIC has extensively reviewed the literature and concluded no changes are required to the therapeutic recommendations of the abacavir dosing guideline based on HLA-B genotype since the original publication in 2012. The 2014 update includes the following additions: * Clinical implementation resources to help implementation of the guidelines into an Electronic

In Current Drug Metabolism, the Clinical Pharmacogenetics Implementation Consortium (CPIC) has defined the standardized operating procedures undertaken for each guideline written. Outlined in the publication is how gene-drug relationships are initially assessed for a potential guideline, how a writing committee with experts in the subject is established, the gathering and

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published updates to the guidelines for the use of genetic test results for cytochrome P450-2D6 (CYP2D6) in codeine dosing. The 2014 update is now available online, as an accepted article preview.Alternate analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. Label recommended

The Genetics/Genomics Competency Center (G2C2) is a free, online resource that provides a collection of high quality educational materials for self-directed learning in genetics or genomics. It is targeted toward health care professionals such as genetic counselors, nurses, physician assistants and pharmacists. The educational information presented consists of journal

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines for the use of genetic test results for DPYD in fluoropyrimidine dosing. The guideline in Clinical Pharmacology and Therapeutics recommends strategies for drug dosing or alternative drug choice in cancer patients who have known variants in the dihydropyrimidine dehydrogenase (DPYD) gene